We demonstrated the abundance of the IFNA17 protein in CHRM4-overexpressing cells and the serum of patients with metastatic prostate cancer, suggesting that IFNA17 is a potential prognostic marker for advanced prostate cancer. Here, CHRM4 is linked to prostate carcinoma.